Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist.
暂无分享,去创建一个
A. Mencacci | E. Cenci | G. Del Sero | C. Montagnoli | A. Bacci | F. Bistoni | L. Romani | E Cenci | A Mencacci | G Del Sero | L Romani | F Bistoni | G. D. Sero | Francesco Bistoni | Luigina Romani | C. F. D'ostiani
[1] E. Anaissie,et al. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] R. Lynch,et al. Augmentation of murine immune responses by amphotericin B. , 1977, Cellular immunology.
[3] R. Coffman,et al. Interleukin‐4 and ‐10 exacerbate candidiasis in mice , 1995, European journal of immunology.
[4] P. Puccetti,et al. Biological Role of Th Cell Subsets in Candidiasis , 1996 .
[5] R. Hay. Overview of the treatment of disseminated fungal infections. , 1991, The Journal of antimicrobial chemotherapy.
[6] J. Billé. Correlation between in vitro and in vivo activity of antifungal agents against yeasts , 1996 .
[7] R. Ashman. Murine candidiasis: Cell‐mediated immune responses correlate directly with susceptibility and resistance to infection , 1990, Immunology and cell biology.
[8] L. Romani,et al. Mechanisms of resistance to fungal infections. , 1995, Current opinion in immunology.
[9] U. Grohmann,et al. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis , 1992, The Journal of experimental medicine.
[10] S. Reed,et al. TGF-beta is important in determining the in vivo patterns of susceptibility or resistance in mice infected with Candida albicans. , 1995, Journal of immunology.
[11] A. Mencacci,et al. CD4+ T-helper-cell responses in mice with low-level Candida albicans infection , 1996, Infection and immunity.
[12] G. Bodey,et al. Azole antifungal agents. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] J. Sobel,et al. The role of cell-mediated immunity in candidiasis. , 1994, Trends in microbiology.
[14] H. Filutowicz,et al. Correlates of cell-mediated immunity in Candida albicans-colonized gnotobiotic mice , 1990, Infection and immunity.
[15] P. Puccetti,et al. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. , 1994, Journal of immunology.
[16] P. Troke,et al. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice , 1985, Antimicrobial Agents and Chemotherapy.
[17] J. Graybill. Future directions of antifungal chemotherapy. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] P. Puccetti,et al. Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. , 1994, The Journal of infectious diseases.
[19] P. Puccetti,et al. A TH1-TH2-like switch in candidiasis: new perspectives for therapy. , 1995, Trends in microbiology.
[20] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[21] J. Little,et al. Immunopotentiating effects of amphotericin B. I. Enhanced contact sensitivity in mice. , 1979, Journal of immunology.
[22] U. Grohmann,et al. Gamma interferon modifies CD4+ subset expression in murine candidiasis , 1992, Infection and immunity.
[23] U. Grohmann,et al. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans. , 1994, Journal of immunology.
[24] R. D. Meyer,et al. Current role of therapy with amphotericin B. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.